Novo Nordisk chair boasts competitive production advantage
The Danish drugmaker’s chair says the company’s production facilities makes it one to watch, and Novo Nordisk is only increasing its investments into expanding capacity in 2023.
by christian bundgaard, translated by daniel pedersen
Novo Nordisk has an advantage on the obesity market, says the company’s chair of the board of directors, Helge Lund to Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
